Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-18T04:35:18.590Z Has data issue: false hasContentIssue false
  • English
  • Français

The Pharmacologic Treatment of Patients With Generalized Anxiety Disorder: Where Are We Now and Where Are We Going?

Published online by Cambridge University Press:  07 November 2014

David S. Baldwin  and
Nupur Tiwari
David S. Baldwin*
Affiliation:
Dr. Baldwin is reader in psychiatry in the Department of Psychiatry at, Royal South Hants Hospital, in Southampton, United Kingdom
*
David S. Baldwin, DM, FRCPsych, University Department of Mental Health, Royal South Hants Hospital, Brintons Terrace, Southampton SO14 0YG, United Kingdom; Tel: 44-2380-825533; Fax: 44-2380-234243; E-mail: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Evidence-based guidelines for the pharmacologic management of patients with generalized anxiety disorder (GAD) recommend initial treatment with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI). However, response rates to initial treatment with an SSRI or SNRI can be disappointing, and it remains impossible to predict reliably which patients will respond positively or negatively to treatment. Due to the dearth of longitudinal studies of outcome in GAD and the relatively small number of placebo-controlled relapse prevention studies, the optimal duration of treatment after a satisfactory response to acute treatment is still uncertain. Furthermore, there have been few studies on the management of patients who do not respond to initial treatment. Also, there is a clear need for further randomized controlled trials of augmentation treatment in patients who do not respond to SSRI, SNRI, or other initial pharmacologic approaches. Future guidelines will be influenced by emerging data with both established and novel drug treatments, and through better identification of patient groups that are likely to respond preferentially to particular interventions.

Type
Research Article
Information
CNS Spectrums , Volume 14 , Issue S3 , 2009 , pp. 5 - 12
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Baldwin, DS, Anderson, IM, Nutt, DJ, et al.Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19(6):567–596.Google Scholar
2.Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. 2006;51(8 suppl 2):9S–91S.Google Scholar
3.Pollack, MH, Zaninelli, R, Goddard, A, et al.Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62(5):350–357.Google Scholar
4.Rickels, K, Zaninelli, R, McCafferty, J, Bellew, K, Iyengar, M, Sheehan, D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160(4):749–756.Google Scholar
5.Rynn, MA, Siqueland, L, Rickels, K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001;158(12):2008–2014.Google Scholar
6.Allgulander, C, Dahl, AA, Austin, C, et al.Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry. 2004;161(9):1642–1649.Google Scholar
7.Brawman-Mintzer, O, Knapp, RG, Rynn, M, Carter, RE, Rickels, K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(6):874–881.Google Scholar
8.Davidson, JR, Bose, A, Korotzer, A, Zheng, H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety. 2004;19(4):234–240.Google Scholar
9.Goodman, WK, Bose, A, Wang, Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005;87(2-3):161–167.Google Scholar
10.Baldwin, DS, Huusom, AK, Maehlum, E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: Randomised, placebo-controlled, double-blind study. Br J Psychiatry. 2006;189:264–272.Google Scholar
11.Baldwin, DS, Ajel, K. The role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2007;3:185–191.Google Scholar
12.Koponen, H, Allgulander, C, Erickson, J, et al.Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007;9(2):100–107.Google Scholar
13.Rynn, M, Russell, J, Erickson, J, et al.Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008;25(3):182–189.Google Scholar
14.Hartford, J, Kornstein, S, Liebowitz, M. et al.Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol. 2007;22(3):167–174.Google Scholar
15.Davidson, JR, DuPont, RL, Hedges, D, Haskins, JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60(8):528–535.Google Scholar
16.Gelenberg, AJ, Lydiard, RB, Rudolph, RL, Aguiar, L, Haskins, JT, Salinas, E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000;283(23):3082–3088.Google Scholar
17.Rickels, K, Pollack, MH, Sheehan, DV, Haskins, JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157(6):968–974.Google Scholar
18.Allgulander, C, Hackett, D, Salinas, E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15–22.Google Scholar
19.Lenox-Smith, AJ, Reynolds, A. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract. 2003;53(495):772–777.Google Scholar
20.Rynn, MA, Riddle, MA, Yeung, PP, Kunz, NR. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry. 2007;164(2):290–300.Google Scholar
21.Pande, AC, Pollack, MH, Crockatt, J, et al.Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20(4):467–471.Google Scholar
22.Pande, AC, Crockatt, JG, Feltner, DE, et al.Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160(3):533–540.Google Scholar
23.Feltner, DE, Crockatt, JG, Dubovsky, SJ, et al.A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23(3):240–249.Google Scholar
24.Rickels, K, Pollack, MH, Feltner, DE, et al.Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62(9):1022–1030.Google Scholar
25.Montgomery, SA, Tobias, K, Zornberg, GL, Kasper, S, Pande, AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67(5):771–782.Google Scholar
26.Pohl, RB, Feltner, DE, Fieve, RR, Pande, AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25(2):151–158.Google Scholar
27.Montgomery, S, Chatamra, K, Pauer, L, Whalen, E, Baldinetti, F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry. 2008;193(5):389–394.Google Scholar
28.Hamilton, M. Hamilton anxiety rating scale (HARS). In: Rush, AJ, Pincus, HA, First, MB, et al. eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:554–557.Google Scholar
29.Martin, JL, Sainz-Pardo, M, Furukawa, TA, Martin-Sanchez, E, Seoane, T, Galán, C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007;21(7):774–782.Google Scholar
30.Bandelow, B, Baldwin, DS, Dolberg, OT, Andersen, HF, Stein, DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry. 2006;67(9):1428–1434.Google Scholar
31.Guy, W. Clinical global impressions (CGI) scale. In: Rush, AJ, Pincus, HA, First, MB, et al. eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:100–102.Google Scholar
32.Ballenger, JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999;60(suppl 22):29–34.Google Scholar
33.Bandelow, B. Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr. 2006;11(10 suppl 12):21–28.Google Scholar
34.Rickels, K, Rynn, M, Iyengar, M, Duff, D. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry. 2006;67(1):41–47.Google Scholar
35.Sheehan, DV. Sheehan disability scale. In: Rush, AJ, Pincus, HA, First, MB, et al. eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:113–115.Google Scholar
36.Hidalgo, RB, Tupler, LA, Davidson, JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21(8):864–872.Google Scholar
37.Mitte, K, Noack, P, Steil, R, Hautzinger, M. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol. 2005;25(2):141–150.Google Scholar
38.National Institute for Clinical Excellence (NICE). Clinical guideline on depression Appendix 20: Clinical evidence statements. Available at: www.nice.org.uk. Accessed January 29, 2009.Google Scholar
39.Altamura, AC, Dell’Osso, B, D’Urso, N, Russo, M, Fumagalli, S, Mundo, E. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectr. 2008;13(5):415–422.Google Scholar
40.Perugi, G, Frare, F, Toni, C, Ruffolo, G, Torti, C. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response. Neuropsychobiology. 2002;46(3):145–149.Google Scholar
41.Rodriguez, BF, Weisberg, RB, Pagano, ME, et al.Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis. 2006;194(2):91–97.Google Scholar
42.Pollack, MH, Meoni, P, Otto, MW, Hackett, D. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003;23(3):250–259.Google Scholar
43.Stein, DJ, Baldwin, DS, Dolberg, OT, Despiegel, N, Bandelow, B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 2006;67(11):1741–1746.Google Scholar
44.Silverstone, PH, Salinas, E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry. 2001;62(7):523–529.Google Scholar
45.Stein, DJ, Andersen, HF, Goodman, WK. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry. 2005;17(2):71–75.Google Scholar
46.Stein, DJ, Baldwin, DS, Baldinetti, F, Mandel, F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008;18(6):422–430.Google Scholar
47.Olatunji, BO, Feldman, G, Smits, JA, et al.Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Depress Anxiety. 2008;25(2):167–171.Google Scholar
48.Downing, RW, Rickels, K. Early treatment response in anxious outpatients treated with diazepam. Acta Psychiatr Scand. 1985;72(6):522–528.Google Scholar
49.Laakmann, G, Schule, C, Lorkowski, G, Baghai, T, Kuhn, K, Ehrentraut, S. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl). 1998;136(4):357–366.Google Scholar
50.Rynn, M, Khalid-Khan, S, Garcia-Espana, JF, Etemad, B, Rickels, K. Early response and 8-week treatment outcome in GAD. Depress Anxiety. 2006;23(8):461–465.Google Scholar
51.Pollack, MH, Kornstein, SG, Spann, ME, Crits-Christoph, P, Raskin, J, Russell, JM. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. 2008;42(14):1176–1184.Google Scholar
52.Baldwin, DS, Stein, DJ, Dolberg, O, Bandelow, B. How long should an initial treatment period be in anxiety disorders and in major depressive disorder? Paper presented at: International Anxiety Disorders Symposium (IADS); March 17–18, 2008; Cape Town, South Africa.Google Scholar
53.Bruce, SE, Yonkers, KA, Otto, MW, et al.Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005;162(6):1179–1187.Google Scholar
54.Geddes, JR, Carney, SM, Davies, C, et al.Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–661.Google Scholar
55.Allgulander, C, Florea, I, Huusom, AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006;9(5):495–505.CrossRefGoogle ScholarPubMed
56.Feltner, D, Wittchen, HU, Kavoussi, R, Brock, J, Baldinetti, F, Pande, AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23(1):18–28.Google Scholar
57.Stocchi, F, Nordera, G, Jokinen, RH, et al.and the Paroxetine Generalized Anxiety Disorder Study Team. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003;64(3):250–258.Google Scholar
58.Davidson, JR, Wittchen, HU, Llorca, PM, et al.Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008;18(9):673–681.Google Scholar
59.Montgomery, SA, Sheehan, DV, Meoni, P, Haudiquet, V, Hackett, D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res. 2002;36(4):209–217.Google Scholar
60.Food and Drug Administration. New controversial clinical trial design gives better long-term data. FDA Week. May 20, 2005.Google Scholar
61.Bech, P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry. 2007;40(4):163–168.Google Scholar
62.Chessick, CA, Allen, MH, Thase, M, et al.Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006;3:CD006115.Google Scholar
63.Mendels, J, Krajewski, TF, Huffer, V, et al.Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry. 1986;47(4):170–174.Google Scholar
64.Bandelow, B, Bobes, J, Ahokas, A, Eggens, I, Liu, S, Brecher, M. Results from a phase III study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder. Int J Psychiatry. 2007;11:314–315.Google Scholar
65.Simon, NM, Connor, KM, LeBeau, RT, et al.Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008;197(4):675–681.Google Scholar
66.Brawman-Mintzer, O, Knapp, RG, Nietert, PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66(10):1321–1325.Google Scholar
67.Pollack, MH, Simon, NM, Zalta, AK, et al.Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59(3):211–215.Google Scholar
68.Stein, DJ, Ahokas, A, Fabiano, A. Agomelatine in generalized anxiety disorder: a randomized, placebo-controlled, study. Eur Neuropsychopharmacol. 2007;17 (suppl 4):S509–S510.Google Scholar
69.Bandelow, B, Seidler-Brandler, U, Becker, A, Wedekind, D, Ruther, E. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry. 2007;8(3):175–187.Google Scholar
70.Connor, KM, Payne, V, Davidson, JR. Kava in generalized anxiety disorder: three placebo-controlled trials. Int Clin Psychopharmacol. 2006;21(5):249–253.Google Scholar
71.Woelk, H, Arnoldt, KH, Kieser, M, Hoerr, R. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2007;41(6):472–480.Google Scholar
72.Herrera-Arellano, A, Jimenez-Ferrer, E, Zamilpa, A, Morales-Valdez, M, Garcia-Valencia, CE, Tortoriello, J. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Planta Med. 2007;73(8):713–717.Google Scholar
73.Baldwin, DS, Garner, MJ. How effective are current drug treatments for anxiety disorders, and how could they be improved? In: Blanchard, R, Blanchard, C, Griebel, G, Nutt, DJ, eds. Handbook of Anxiety and Fear. 17th ed. Amsterdam: Elsevier; 2008:395–411.Google Scholar
74.Borkovec, TD, Ruscio, AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 11):37–42.Google Scholar
75.Borkovec, TD, Newman, MG, Castonguay, LG. Cognitive-behavioral therapy for generalized anxiety disorder with integrations from interpersonal and experiential therapies. CNS Spectr. 2003;8(5):382–389.Google Scholar
76.Reynolds, GP, Templeman, LA, Zhang, ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):1021–1028.Google Scholar
77.Harmer, CJ, Bhagwagar, Z, Perrett, DI, Vollm, BA, Cowen, PJ, Goodwin, GM. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology. 2003;28(1):148–152.Google Scholar
78.Chamberlain, SR, Muller, U, Blackwell, AD, Robbins, TW, Sahakian, BJ. Noradrenergic modulation of working memory and emotional memory in humans. Psychopharmacology (Berl). 2006;188(4):397–407.Google Scholar
79.Mogg, K, Baldwin, DS, Brodrick, P, Bradley, BP. Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. Psychopharmacology (Berl). 2004;176(3-4):466–470.Google Scholar